SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Roberto Bassi, Alessia Fornoni, Alessandro Doria, Paolo Fiorina, CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease, Diabetologia, 2016, 59, 1, 21

    CrossRef

  2. 2
    Thierry Schaeverbeke, Marie-Elise Truchetet, Marie Kostine, Thomas Barnetche, Bernard Bannwarth, Christophe Richez, Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice, Rheumatology, 2016, 55, 2, 210

    CrossRef

  3. 3
    Maciej Tarnowski, Agnieszka Paradowska-Gorycka, Ewa Dąbrowska-Zamojcin, Michal Czerewaty, Sylwia Słuczanowska-Głąbowska, Andrzej Pawlik, The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy, Expert Opinion on Drug Metabolism & Toxicology, 2016, 12, 1, 41

    CrossRef

  4. 4
    Walter Reinisch, Josef Smolen, Biosimilar safety factors in clinical practice, Seminars in Arthritis and Rheumatism, 2015, 44, 6, S9

    CrossRef

  5. 5
    Michael Schiff, Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow, Current Treatment Options in Rheumatology, 2015, 1, 4, 334

    CrossRef

  6. 6
    Machaon Bonafede, Barbara H. Johnson, Nicole Princic, Neel Shah, David J. Harrison, Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis, Journal of Medical Economics, 2015, 18, 5, 376

    CrossRef

  7. 7
    Cem Gabay, Myriam Riek, Almut Scherer, Axel Finckh, Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry, Rheumatology, 2015, 54, 9, 1664

    CrossRef

  8. 8
    P. Emery, G. R. Burmester, V. P. Bykerk, B. G. Combe, D. E. Furst, E. Barre, C. S. Karyekar, D. A. Wong, T. W. J. Huizinga, Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period, Annals of the Rheumatic Diseases, 2015, 74, 1, 19

    CrossRef

  9. 9
    AS Siebuhr, AC Bay-Jensen, JM Jordan, CF Kjelgaard-Petersen, C Christiansen, SB Abramson, M Attur, F Berenbaum, V Kraus, MA Karsdal, Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?, Scandinavian Journal of Rheumatology, 2015, 1

    CrossRef

  10. 10
    Koichi Amano, Tsukasa Matsubara, Takaaki Tanaka, Hiroshi Inoue, Mitsuhiro Iwahashi, Toshihisa Kanamono, Teruaki Nakano, Shoichi Uchimura, Tomomaro Izumihara, Akira Yamazaki, Chetan S. Karyekar, Tsutomu Takeuchi, Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders, Modern Rheumatology, 2015, 25, 5, 665

    CrossRef

  11. 11
    J.R. Kalden, Pathogene Zellen der rheumatischen Entzündung als Ziele moderner Therapien, Zeitschrift für Rheumatologie, 2015, 74, 1, 8

    CrossRef

  12. 12
    Edward Keystone, Abdulaziz Alkhalaf, Mosaab Makkawy, Subcutaneous abatacept in rheumatoid arthritis: current update, Expert Opinion on Biological Therapy, 2015, 15, 8, 1221

    CrossRef

  13. 13
    Nicolaas D. Vlieland, Helga Gardarsdottir, Marcel L. Bouvy, Toine C. G. Egberts, Bart J. F. van den Bemt, The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range, Rheumatology, 2015, kev394

    CrossRef

  14. 14
    Maria Greenwald, Leszek Szczepanski, Alastair Kennedy, Melissa Veenhuizen, Wendy J Komocsar, Emery Polasek, Kelly Guerrettaz, Pierre-Yves Berclaz, Chin Lee, A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis, Arthritis Research & Therapy, 2014, 16, 4

    CrossRef

  15. 15
    V. Strand, B. Cronstein, Biosimilars: how similar?, Internal Medicine Journal, 2014, 44, 3
  16. 16
    Nicole W Tsao, Kam Shojania, Carlo A Marra, Cost–effectiveness of abatacept for moderate-to-severe rheumatoid arthritis, Expert Review of Pharmacoeconomics & Outcomes Research, 2014, 14, 1, 9

    CrossRef

  17. 17
    Emilio Martín Mola, Alejandro Balsa, Víctor Martínez Taboada, José Luis Marenco, Federico Navarro Sarabia, Juan Gómez-Reino, José María Álvaro-Gracia, José Andrés Román Ivorra, Leticia Lojo, Chamaida Plasencia, Loreto Carmona, Documento práctico para el uso de abatacept subcutáneo, Reumatología Clínica, 2014, 10, 4, 218

    CrossRef

  18. 18
    Mitsuhiro Iwahashi, Hiroshi Inoue, Tsukasa Matsubara, Takaaki Tanaka, Koichi Amano, Toshihisa Kanamono, Teruaki Nakano, Shoichi Uchimura, Tomomaro Izumihara, Akira Yamazaki, Chetan S. Karyekar, Tsutomu Takeuchi, Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study, Modern Rheumatology, 2014, 24, 6, 885

    CrossRef

  19. 19
    M. Gaubitz, K. Krüger, J.-P. Haas, Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis, Zeitschrift für Rheumatologie, 2014, 73, 10, 942

    CrossRef

  20. 20
    T. Heise, L. Nosek, S. Dellweg, E. Zijlstra, K. A. Præstmark, J. Kildegaard, G. Nielsen, T. Sparre, Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial, Diabetes, Obesity and Metabolism, 2014, 16, 10
  21. 21
    Emilio Martín Mola, Alejandro Balsa, Víctor Martínez Taboada, José Luis Marenco, Federico Navarro Sarabia, Juan Gómez-Reino, José María Álvaro-Gracia, José Andrés Román Ivorra, Leticia Lojo, Chamaida Plasencia, Loreto Carmona, Practice Guidelines for the Use of Subcutaneous Abatacept, Reumatología Clínica (English Edition), 2014, 10, 4, 218

    CrossRef

  22. 22
    Nozomi Iwanaga, Tomoki Origuchi, Kaoru Terada, Yukitaka Ueki, Yasuhiro Kamo, Noboru Kinoshita, Nobuhisa Yonemitsu, Shin-Ya Kawashiri, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Atsushi Kawakami, Rheumatoid arthritis complicated with severe liver injury during treatment with abatacept, Modern Rheumatology, 2014, 24, 5, 874

    CrossRef

  23. 23
    A. Souto, J. R. Maneiro, E. Salgado, L. Carmona, J. J. Gomez-Reino, Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies, Rheumatology, 2014, 53, 10, 1872

    CrossRef

  24. 24
    Gillian M. Keating, Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis, Drugs, 2013, 73, 10, 1095

    CrossRef

  25. 25
    Esther F Vicente Rabaneda, Gabriel Herrero-Beaumont, Santos Castañeda, Update on the use of abatacept for the treatment of rheumatoid arthritis, Expert Review of Clinical Immunology, 2013, 9, 7, 599

    CrossRef